These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18780163)

  • 1. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
    Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sequential Monte Carlo approach to derive sampling times and windows for population pharmacokinetic studies.
    McGree JM; Drovandi CC; Pettitt AN
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):519-26. PubMed ID: 22847735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
    Dokoumetzidis A; Aarons L
    J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of some practical sampling strategies for population pharmacokinetic studies.
    Jonsson EN; Wade JR; Karlsson MO
    J Pharmacokinet Biopharm; 1996 Apr; 24(2):245-63. PubMed ID: 8875349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of population pharmacokinetic experiments using prior information.
    Ogungbenro K; Aarons L
    Xenobiotica; 2007; 37(10-11):1311-30. PubMed ID: 17968747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of individual and population designs using Splus.
    Retout S; Mentré F
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal sampling schedule design for populations of patients.
    Tam VH; Preston SL; Drusano GL
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2888-91. PubMed ID: 12936990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments.
    Ogungbenro K; Graham G; Gueorguieva I; Aarons L
    Comput Methods Programs Biomed; 2005 Nov; 80(2):115-25. PubMed ID: 16139390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.